The study of the efficacy of combined medicines of quercetin and glucosamine derivatives in rats with the end-stage renal failure
Keywords:quercetin, N-acetylglucosamine, glucosamine hydrochloride, end-stage renal failure, adenine-induced nephropathy
Chronic kidney disease (CKD) is the most significant pathology among diseases of the urinary system, which leads to the inevitable development of renal failure. Currently, there are no effective treatments for the end-stage form of CKD in clinical practice.
Aim. To study of the effect of combined medicines of quercetin with glucosamine derivatives in the experiment using various routes of administration on the course of the end-stage renal failure.
Materials and methods. The study was performed on the model of adenine-induced nephropathy in rats. Test samples were administered intragastrically (80 mg/kg) and intramuscularly (30 mg/kg) for 4 weeks starting in 4 weeks after beginning of the experiment. Corvitin was used as a reference drug in the dose of 34 mg/kg. The efficacy of test drugs was assessed by indicators of the kidney functional state and nitrogen metabolism.
Results. In 8 weeks after the pathology simulation under the influence of both test objects a positive effect on the course of renal failure was observed. In this case, an injection combination of quercetin with N-acetylglucosamine significantly (p<0.05) exceeded the efficacy of the oral combination. Under its influence, there was an increase in glomerular filtration and urinary excretion of creatinine and urea. It indicates the normalization of the kidney functional state and nitrogen metabolism. Moreover, this combination was significantly (p<0.05) superior to the Corvitin effect by the efficacy level.
Conclusions. In conditions of the end-stage renal failure in rats the injection combination of quercetin with N-acetylglucosamine was highly effective. It allows considering this combination to be a promising medicine for treating CKD at the IV-V stages.
Lerma, E., Sparks, M., Topf, J. (2019). Nephrology Secrets, 4th edition. Philadelphia: Elsevier, 654.
Feehally, J., Floege, J., Johnson, R. J., Tonelli, M. (2019). Comprehensive Clinical Nephrology, 6th edition. Philadelphia: Elsevier, 1570.
Gilbert, S. J., Weiner, D. E. (2018). National Kidney Foundation’s Primer on Kidney Diseases, 7th edition. Philadelphia: Elsevier, 680.
Turner, N. N., Turner, N. N., Lameire, N., Goldsmith, D. J., Winearls, C. G., Himmelfarb, J., & Remuzzi, G. (Eds.). (2015). Oxford Textbook of Clinical Nephrology. Oxford Medicine Online. https://doi.org/10.1093/med/9780199592548.001.0001
Shebeko, S. K., Zupanets, I. A., Popov, O. S. Tarasenko, O. O., Shalamay, A. S. (2018). Effects of Quercetin and Its Combinations on Health. Polyphenols: Mechanisms of Action in Human Health and Disease, 2nd edition. London: Academic Press, 373–394.
Shebeko, S. K., Zupanets, I. A., Tarasenko, O. O. (2019). Nephroprotective effect of N-acetylglucosamine in rats with acute kidney injury. Česká a slovenská farmacie, 68(4), 173–179.
Shebeko, S. K., Zupanets, I. A., Popov, O. S. (2019). N-Acetylglucosamine is the most effective glucosamine derivative for the treatment of membranous nephropathy in rats. Pharmazie, 74(11), 667–670.
Shebeko, S. K., Zupanets, I. A., Propisnova, V. V. (2020). N-acetylglucosamine increases the efficacy of quercetin in the treatment of experimental acute kidney injury. Journal of Pharmacy & Pharmacognosy Research, 8(1), 53–63.
Guide for the care and use of laboratory animals, 8th edition. (2011). Washington : The National Academies Press, 246.
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes (2010). Official Journal of the European Union, L276, 33–79.
Kashioulis, P., Lundgren, J., Shubbar, E., Nguy, L., Saeed, A., Guron, C. W., & Guron, G. (2018). Adenine-Induced Chronic Renal Failure in Rats: A Model of Chronic Renocardiac Syndrome with Left Ventricular Diastolic Dysfunction but Preserved Ejection Fraction. Kidney and Blood Pressure Research, 43(4), 1053–1064. https://doi.org/10.1159/000491056
Kamyshnikov, V. S. (2016). Metody klinicheskikh laboratornykh issledovanii. Moscow: MEDpress–inform, 736.
Islam, M. A., Al-Shiha, A. (2018). Foundations of Biostatistics. Singapore: Springer, 474.
Yang, H., Song, Y., Liang, Y., & Li, R. (2018). Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease. Medical Science Monitor, 24, 4760–4766. https://doi.org/10.12659/msm.909259
Layal, K., Perdhana, I. S., Louisa, M., Estuningtyas, A., & Soetikno, V. (2017). The effects of quercetin on oxidative stress and fibrosis markers in chronic kidney disease rat model. Medical Journal of Indonesia, 26(3), 169–177. https://doi.org/10.13181/mji.v26i3.1462
Vargas, F., Romecín, P., García-Guillén, A. I., Wangesteen, R., Vargas-Tendero, P., Paredes, M. D., … García-Estañ, J. (2018). Flavonoids in Kidney Health and Disease. Frontiers in Physiology, 9. https://doi.org/10.3389/fphys.2018.00394
Park, J., Lee, S.-Y., Ooshima, A., Yang, K.-M., Kang, J. M., Kim, Y.-W., & Kim, S.-J. (2013). Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF-β signaling. Journal of Molecular Medicine, 91(11), 1273–1284. https://doi.org/10.1007/s00109-013-1086-1
Hu, J., Chen, R., Jia, P., Fang, Y., Liu, T., Song, N., … Ding, X. (2017). Augmented O-GlcNAc signaling via glucosamine attenuates oxidative stress and apoptosis following contrast-induced acute kidney injury in rats. Free Radical Biology and Medicine, 103, 121–132. https://doi.org/10.1016/j.freeradbiomed.2016.12.032
Fu, Y., Lin, Q., Gong, T., Sun, X., & Zhang, Z. (2016). Renal-targeting triptolide-glucosamine conjugate exhibits lower toxicity and superior efficacy in attenuation of ischemia/reperfusion renal injury in rats. Acta Pharmacologica Sinica, 37(11), 1467–1480. https://doi.org/10.1038/aps.2016.44
Baynes, J. W., Dominiczak, M. H. (2019). Medical Biochemistry, 5th edition. Philadelphia: Elsevier, 712.
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).